3M (US), Novartis AG (Switzerland), Pfizer Inc. (US), Johnson & Johnson Services, Inc. (US), Janssen Global Services, LLC (US), BD (US) are turning all the heads in the Global Nasal Drug Delivery Technology Market because of their product launches, their researches, joint ventures, merges, and accusations which are in turn affecting the sales, import, export and revenue at a global level.
This report by Data Bridge Market Research brings to you all the companies profiles needed to be in the competition for the Global Nasal Drug Delivery Technology Market. With the help of SWOT analysis the report tells you about all the market restrain and drivers to be followed in the forecast period of 2019-2026 while also explaining what the Global Nasal Drug Delivery Technology Market definition, classifications, applications, and engagements are and providing with all the figures of CAGR levels in the historic year 2017, base year 2018 and forecast year 2019-2026.
“Global Nasal Drug Delivery Technology Market is expected to rise gradually to an estimated value of USD 97.24 billion by 2026, registering a CAGR of 7.5% in the forecast period of 2019-2026 with the annual sales of USD 54.52 billion in 2018”. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.
Nasal drug delivery technology is the method of giving drug through the nasal route. The nasal route of administration helps the drug to get the direct access into systemic circulation. Drugs administered through the nasal route are accessible in various dosage forms, for example, liquid spray, liquid drops, suspension spray, Aerosol, gel etc.
According to World Health Organization, there were an estimated 22.7% people suffers from nasal congestion, almost more than half of these incidences could have been avoided with the availability of proper medical equipment and devices for healthcare procedures. This significant number is expected to act as a driver to the market growth.
Increasing prevalence of chronic diseases is going to drive the growth of the market.
Rising numbers of pediatric and geriatric patients is going to drive the growth of the market.
Growing acceptance of self-administration applies is going to drive the growth of the market.
Regulatory hindrances is going to restrain the market.
Over-the-counter nasal drugs
Key Developments in the Market: Global Nasal Drug Delivery Technology Market
On 20th September, 2017, OptiNose US Inc. launched an innovative product, XHANCE, which is the only FDA-approved prescription nasal spray that uses an Exhalation Delivery System to treat nasal polyps. It will leverage the growth of the product line of the company.
On 28th March 2018, pSivida acquired specialty biopharmaceutical company, Icon Bioscience Inc., and rebranded as EyePoint Pharmaceuticals. By acquiring the company pSivida owned Icon’s pipeline products and entered into a new segment which is going to help company to gain new heights.
Order a Copy of This Research Report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-nasal-drug-delivery-technology-market
Segmentation: Global Nasal Drug Delivery Technology Market
By Therapeutic Application
Allergic & Non-Allergic Rhinitis
By Dosage Form
Nasal Drops & Liquids
By End Users
Ambulatory Surgery Centers
Middle East & Africa
Global nasal drug delivery technology market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of nasal drug delivery technology market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Some of the major competitors currently working in the nasal drug delivery technology market are 3M (US), Novartis AG (Switzerland), Pfizer Inc. (US), Johnson & Johnson Services, Inc. (US), Janssen Global Services, LLC (US), BD (US), GlaxoSmithKline plc (UK), Alkermes (Ireland), Vectura Group plc (UK), Kurve Technology, Inc. (US), OptiNose US Inc. (US), Merck & Co., Inc. (US), Procter & Gamble (US), Teleflex Incorporated., (US), Antares Pharma. (US), Aradigm Corporation. (US), Generex Biotechnology Corp. (Canada), AptarGroup, Inc. (US), EyePoint Pharmaceuticals (US), NanoPass (Ireland) among others
Key reason to Purchase the report
- To describe and forecast the Global Nasal Drug Delivery Technology Market, in terms of value, by process, product type, and industry.
- To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, and detail the competitive landscape for market leaders
- To describe and forecast the market, in terms of value, for various segments, by region North America, Europe, Asia Pacific (APAC), and Rest of the World (RoW)
- To provide detailed information regarding the major factors (drivers, restraints, opportunities, and challenges) influencing the Global Nasal Drug Delivery Technology Market growth
- Market Development: Comprehensive information about emerging markets.
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contribution to the overall market
Grab Your Report at an Impressive Discount! Please Click Here @ https://www.databridgemarketresearch.com/request-a-discount/global-nasal-drug-delivery-technology-market
About Data Bridge Market Research
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475